LONDON, UK / ACCESSWIRE / October 11, 2022 / Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot…
Read More
About The Author
